Amundi Purchases 513,255 Shares of Bristol Myers Squibb Company $BMY

Amundi boosted its position in shares of Bristol Myers Squibb Company (NYSE:BMY) by 9.7% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 5,780,139 shares of the biopharmaceutical company’s stock after buying an additional 513,255 shares during the period. Amundi owned approximately 0.28% of Bristol Myers Squibb worth $275,308,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in BMY. Marshall Wace LLP bought a new position in Bristol Myers Squibb in the second quarter valued at approximately $221,000. First Trust Advisors LP boosted its holdings in shares of Bristol Myers Squibb by 393.2% in the 2nd quarter. First Trust Advisors LP now owns 4,592,548 shares of the biopharmaceutical company’s stock valued at $212,589,000 after purchasing an additional 3,661,431 shares in the last quarter. Guggenheim Capital LLC increased its stake in shares of Bristol Myers Squibb by 0.3% in the 2nd quarter. Guggenheim Capital LLC now owns 669,451 shares of the biopharmaceutical company’s stock valued at $30,989,000 after purchasing an additional 1,944 shares during the last quarter. EverSource Wealth Advisors LLC raised its holdings in shares of Bristol Myers Squibb by 4.1% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 7,431 shares of the biopharmaceutical company’s stock worth $344,000 after buying an additional 292 shares in the last quarter. Finally, Raab & Moskowitz Asset Management LLC lifted its position in shares of Bristol Myers Squibb by 33.9% during the 2nd quarter. Raab & Moskowitz Asset Management LLC now owns 21,420 shares of the biopharmaceutical company’s stock worth $992,000 after buying an additional 5,425 shares during the last quarter. 76.41% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on BMY shares. Scotiabank reiterated a “sector perform” rating and issued a $53.00 target price (up previously from $45.00) on shares of Bristol Myers Squibb in a research report on Thursday. Wall Street Zen upgraded shares of Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 8th. Sanford C. Bernstein reiterated a “market perform” rating on shares of Bristol Myers Squibb in a research report on Monday, November 3rd. Weiss Ratings restated a “hold (c-)” rating on shares of Bristol Myers Squibb in a research report on Tuesday, October 14th. Finally, Truist Financial set a $65.00 target price on shares of Bristol Myers Squibb in a research note on Wednesday. Four analysts have rated the stock with a Buy rating and fifteen have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $55.25.

Bristol Myers Squibb Stock Performance

Shares of Bristol Myers Squibb stock opened at $52.16 on Friday. The stock has a market cap of $106.18 billion, a price-to-earnings ratio of 17.62, a P/E/G ratio of 7.95 and a beta of 0.29. Bristol Myers Squibb Company has a twelve month low of $42.52 and a twelve month high of $63.33. The company’s fifty day moving average is $46.21 and its 200 day moving average is $46.78. The company has a quick ratio of 1.17, a current ratio of 1.27 and a debt-to-equity ratio of 2.39.

Bristol Myers Squibb (NYSE:BMY) last announced its earnings results on Thursday, October 30th. The biopharmaceutical company reported $1.63 EPS for the quarter, topping the consensus estimate of $1.52 by $0.11. The firm had revenue of $12.22 billion for the quarter, compared to the consensus estimate of $11.75 billion. Bristol Myers Squibb had a return on equity of 76.53% and a net margin of 12.57%.The business’s quarterly revenue was up 2.8% compared to the same quarter last year. During the same period in the previous year, the business earned $1.80 EPS. Bristol Myers Squibb has set its FY 2025 guidance at 6.400-6.600 EPS. Sell-side analysts forecast that Bristol Myers Squibb Company will post 6.74 EPS for the current year.

Bristol Myers Squibb Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, November 3rd. Shareholders of record on Friday, October 3rd were given a dividend of $0.62 per share. This represents a $2.48 dividend on an annualized basis and a yield of 4.8%. The ex-dividend date of this dividend was Friday, October 3rd. Bristol Myers Squibb’s dividend payout ratio is currently 83.78%.

Bristol Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.